Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Income from Continuing Operations (2020 - 2026)

Opus Genetics has reported Income from Continuing Operations over the past 12 years, most recently at 65535000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 699.79% to 65535000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 106932000.0 through Mar 2026, down 82.42% year-over-year, with the annual reading at 49591000.0 for FY2025, 13.8% up from the prior year.
  • Income from Continuing Operations was 65535000.0 for Q1 2026 at Opus Genetics, down from 16523000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 33941000.0 in Q4 2022 and troughed at 65535000.0 in Q1 2026.
  • The 5-year median for Income from Continuing Operations is 7106000.0 (2024), against an average of 9691529.41.
  • Year-over-year, Income from Continuing Operations surged 637.64% in 2022 and then crashed 699.79% in 2026.
  • A 5-year view of Income from Continuing Operations shows it stood at 33941000.0 in 2022, then plummeted by 114.13% to 4795000.0 in 2023, then tumbled by 632.74% to 35135000.0 in 2024, then skyrocketed by 52.97% to 16523000.0 in 2025, then tumbled by 296.63% to 65535000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRD's Income from Continuing Operations are 65535000.0 (Q1 2026), 16523000.0 (Q4 2025), and 17454000.0 (Q3 2025).